



Johannes Stallhofer

Kontakt

Johannes Stallhofer

Publikationen (16)

Stallhofer J, Veith L, Diegelmann J, Probst P, Brand S, Schnitzler F, Olszak T, Török H, Mayerle J, Stallmach A, Beigel F. Iron Deficiency in Inflammatory Bowel Disease Is Associated With Low Levels of Vitamin D Modulating Serum Hepcidin and Intestinal Ceruloplasmin Expression. *Clin Transl Gastroenterol* 2022; 13:e00450.

Schnitzler F, Friedrich M, Angelberger M, Diegelmann J, Stallhofer J, Wolf C, Dütschler J, Truniger S, Olszak T, Beigel F, Tillack C, Lohse P, Brand S. Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgery. *PloS one* 2020; 15:e0236421.

Stallhofer J, Beigel F, Schnitzler F, Tillack-Schreiber C, Glas J, Lohse P, Wetzke M, Konrad-Zerna A, Friedrich M, Brand S. Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF- α and Modulated by IL23R Genotype Status. *Inflamm Bowel Dis* 2015; 21:2327-40.

Schnitzler F, Grüner N, Rust C, Guba M, Denk G, Zachoval R, Göke B, Tillack C, Beigel F, Olszak T, Angelberger M, Wolf C, Karbalai N, Habicht A, Fischereider M, Schönemarck U, Stallhofer J, Friedrich M, Brand S. Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort. *PloS one* 2015; 10:e0135807.

Schnitzler F, Lohse P, Glas J, Göke B, Beigel F, Tillack C, Olszak T, Diegelmann J, Angelberger M, Stallhofer J, Wolf C, Friedrich M, Brand S. The NOD2 Single Nucleotide Polymorphism rs72796353 (IVS4+10 A>C) Is a Predictor for Perianal Fistulas in Patients with Crohn's Disease in the Absence of Other NOD2 Mutations. *PloS one* 2015; 10:e0116044.

Schnitzler F, Lohse P, Glas J, Göke B, Stallhofer J, Tillack C, Beigel F, Olszak T, Diegelmann J, Angelberger M, Wolf C, Friedrich M, Brand S. The NOD2 p.Leu1007fsX1008 mutation (rs2066847) is a stronger predictor of the clinical course of Crohn's disease than the FOXO3A intron variant rs12212067. *PloS one* 2014; 9:e108503.

Tillack C, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schaubert J, Wollenberg A, Maier H, Wetzke M, Ehmann L, Friedrich M, Laubender R, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Brand S. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon- γ -expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. *Gut* 2013; 63:567-77.

Glas J, Czamara D, Diegelmann J, Göke B, Friedrich M, Steib C, Beigel F, Wetzke M, Tsekere E, Olszak T, Fries C, Stallhofer J, Bues S, Seiderer J, Brand S. IRGM variants and susceptibility to inflammatory bowel disease in the German population. *PloS one* 2013; 8:e54338.

Glas J, Czamara D, Diegelmann J, Ochsenkühn T, Göke B, Wetzke M, Steib C, Stallhofer J, Beigel F, Friedrich M, Tillack C, Fries C, Olszak T, Wagner J, Seiderer J, Brand S. Analysis of IL12B gene variants in inflammatory bowel disease. *PloS one* 2012; 7:e34349.

Glas J, Czamara D, Diegelmann J, Karbalai N, Ochsenkühn T, Göke B, Steib C, Friedrich M, Stallhofer J, Tillack C, Beigel F, Wetzke M, Olszak T, Seiderer J, Wagner J, Brand S. PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background. *PloS one* 2012; 7:e33682.

Schnitzler F, Seiderer J, Stallhofer J, Brand S. Dominant disease-causing effect of NOD2 mutations in a family with all family members affected by Crohn's disease. *Inflamm Bowel Dis* 2011; 18:395-6.

Stallhofer J, Denk G, Glas J, Laubender R, Göke B, Rust C, Brand S, Pust T. Analysis of IL2/IL21 gene variants in cholestatic liver diseases reveals an association with primary sclerosing cholangitis. *Digestion* 2011; 84:29-35.

Jürgens M, Ochsenkühn T, Glas J, Göke B, Lohse P, Tillack C, Schnitzler F, Stallhofer J, Pfennig S, Beigel F, Wetzke M, Wagner J, Seiderer J, Weidinger M, Hartl F, Laubender R, Brand S. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. *Am J Gastroenterol* 2010; 105:1811-9.

Glas J, Müller-Myhsok B, Ochsenkühn T, Göke B, Lohse P, Folwaczny M, Koletzko S, Lacher M, Schiemann U, Griga T, Epplen J, Klein W, Pfennig S, Wetzke M, Ripke S, Stallhofer J, Brand S. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. *Am J Gastroenterol* 2009; 104:1737-44.

Glas J, Klein W, Epplen J, Schiemann U, Mussack T, Lohse P, Göke B, Ochsenkühn T, Folwaczny M, Müller-Myhsok B, Griga T, Jürgens M, Stallhofer J, Seiderer J, Pasciuto G, Tillack C, Diegelmann J, Pfennig S, Konrad A, Schmechel S, Wetzke M, Török H, Brand S. rs224136 on chromosome 10q21.1 and variants in PHOX2B, NCF4, and FAM92B are not major genetic risk factors for susceptibility to Crohn's disease in the German population. *Am J Gastroenterol* 2009; 104:665-72.

Seiderer J, Lohse P, Müller-Myhsok B, Ochsenkühn T, Göke B, Konrad A, Schmechel S, Jürgens M, Pfennig S, Tillack C, Stallhofer J, Glas J, Diegelmann J, Elben I, Brand S. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. *Inflamm Bowel Dis* 2008; 14:437-45.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch